Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 250

1.

Rapamycin, proliferation and geroconversion to senescence.

Blagosklonny MV.

Cell Cycle. 2018 Dec 12:1-11. doi: 10.1080/15384101.2018.1554781. [Epub ahead of print]

PMID:
30541374
2.

Disease or not, aging is easily treatable.

Blagosklonny MV.

Aging (Albany NY). 2018 Nov 17;10(11):3067-3078. doi: 10.18632/aging.101647.

3.

Does rapamycin slow down time?

Blagosklonny MV.

Oncotarget. 2018 Jul 13;9(54):30210-30212. doi: 10.18632/oncotarget.25788. eCollection 2018 Jul 13. No abstract available.

4.

Correction: Librarians against scientists: Oncotarget's lesson.

Blagosklonny MV.

Oncotarget. 2018 Mar 13;9(19):15167. doi: 10.18632/oncotarget.24692. eCollection 2018 Mar 13.

5.

Librarians against scientists: Oncotarget's lesson.

Blagosklonny MV.

Oncotarget. 2018 Jan 19;9(5):5515-5516. doi: 10.18632/oncotarget.24272. eCollection 2018 Jan 19. No abstract available. Erratum in: Oncotarget. 2018 Mar 13;9(19):15167.

6.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

7.

While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.

Leontieva OV, Blagosklonny MV.

Oncotarget. 2017 May 11;8(65):109848-109856. doi: 10.18632/oncotarget.17827. eCollection 2017 Dec 12.

8.

From rapalogs to anti-aging formula.

Blagosklonny MV.

Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033. Review.

9.

Gerosuppression by pan-mTOR inhibitors.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2016 Dec 30;8(12):3535-3551. doi: 10.18632/aging.101155.

10.

Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Oncotarget. 2015 Sep 15;6(27):23238-48.

11.

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB.

Oncotarget. 2015;6(12):9718-27.

12.

Rejuvenating immunity: "anti-aging drug today" eight years later.

Blagosklonny MV.

Oncotarget. 2015 Aug 14;6(23):19405-12.

13.

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.

Leontieva OV, Blagosklonny MV.

Oncotarget. 2014 Dec 30;5(24):12715-27.

14.

Gerosuppression in confluent cells.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2014 Dec;6(12):1010-8.

15.

Fasting levels of hepatic p-S6 are increased in old mice.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(17):2656-9. doi: 10.4161/15384101.2014.949150.

16.

Comparison of rapamycin schedules in mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(21):3350-6. doi: 10.4161/15384101.2014.970491.

17.

Geroconversion: irreversible step to cellular senescence.

Blagosklonny MV.

Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. Review.

18.

Koschei the immortal and anti-aging drugs.

Blagosklonny MV.

Cell Death Dis. 2014 Dec 4;5:e1552. doi: 10.1038/cddis.2014.520. Review.

19.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

20.

Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8832-7. doi: 10.1073/pnas.1405723111. Epub 2014 Jun 2.

Supplemental Content

Loading ...
Support Center